Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
CA 2487362 C · Owner: Donath, Marc · Inventors: Donath, Marc
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Substances that inhibit the action of the members of the IL-1 /NF- B pathway can be used for protecting and preserving -cell mass and function in prediabetic and diabetic type 2 patients. Specifically the present invention , relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 2003 and granted February 21, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 25, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.